Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
The grants are expected to be received over the next three years, commencing March 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Subscribe To Our Newsletter & Stay Updated
